COMPANY OVERVIEW

Saghmos Therapeutics' is developing ST-62516 to prevent cardiorenal complications of contrast-induced acute kidney injury. We are poised to initiate a Phase 3 study for ST-62516 in 2021.

---

LOCATION

None, CT, USA

---

THERAPEUTIC AREAS

Cardiovascular Disease

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Nov 17, 2021

Saghmos Therapeutics Announces Issuance of US Patent for ST-62516 for the Reduction of Kidney Injury in Patients with Chronic Kidney Disease Undergoing Contrast Procedures

Mar 20, 2018

Saghmos Therapeutics to Present at the 25th BioCentury Future Leaders Conference in New York

Feb 8, 2018

Saghmos Therapeutics to Present at BIO CEO Conference in New York

For More Press Releases

---